• Subscribe
  • Magazine
  • Videos
  • Advertise
  • About Us
  • Smart Water Summit
  • Wastewater Summit
    • Recent Quotes
    My Watchlist
    Indicators
    WaterWorld Market Index
    Markets
    Stocks
    ETFs
    Tools
    Markets:
    Overview
    News
    Currencies
    International
    Treasuries

    Cellectar Biosciences, Inc. - Common Stock (NQ:CLRB)

    2.800 -0.100 (-3.44%)
    Streaming Delayed Price Updated: 11:11 AM EST, Mar 5, 2026 Add to My Watchlist
    Quote
    Overview Detailed Quote Charting Historical Prices
    News
    All News News Headlines Press Releases
    Research
    Quarterly Reports Insider Filings Other Filings

    Price and Volume

    Detailed Quote
    Volume 15,818
    Open 2.920
    Bid (Size) 2.750 (2,000)
    Ask (Size) 2.810 (400)
    Prev. Close 2.900
    Today's Range 2.800 - 2.950
    52wk Range 2.450 - 20.59
    Shares Outstanding 3,192,040
    Dividend Yield N/A
    Chart for (: )
    Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

    Top News

    More News
    News headline image
    Cellectar (CLRB) Q4 2025 Earnings Call Transcript ↗
    Cellectar (CLRB) Q4 2025 Earnings Call Transcript 
    Via The Motley Fool
    Topics Earnings Intellectual Property
    News headline image
    Cellectar Biosciences Reports Financial Results for Year Ended 2025 and Provides Corporate Updates
    From Cellectar Biosciences, Inc.
    Via GlobeNewswire

    Performance

    YTD
    -19.3%
    -19.3%
    1 Month
    -11.1%
    -11.1%
    3 Month
    -24.1%
    -24.1%
    6 Month
    -41.4%
    -41.4%
    1 Year
    -67.3%
    -67.3%

    More News

    Read More
    News headline image
    Cellectar Biosciences to Report Full Year Financial Results and Host a Conference Call on Wednesday, March 4, 2026
    From Cellectar Biosciences, Inc.
    Via GlobeNewswire
    News headline image
    Cellectar Biosciences Expands Global Intellectual Property Estate
    From Cellectar Biosciences, Inc.
    Via GlobeNewswire
    News headline image
    Earnings Scheduled For November 13, 2025 ↗
    Via Benzinga
    News headline image
    Cellectar Biosciences to Highlight Strategic Initiatives for 2026 at Upcoming Biotech Showcase during 44th Annual JP Morgan Healthcare Conference
    From Cellectar Biosciences, Inc.
    Via GlobeNewswire
    News headline image
    Cellectar Biosciences Announces Strategic Supply Agreement with Ionetix for Actinium-225 and Astatine-211 to Advance Targeted Alpha Therapies
    From Cellectar Biosciences, Inc.
    Via GlobeNewswire
    News headline image
    Cellectar Biosciences Reports Third Quarter 2025 Financial Results and Provides Corporate Update
    From Cellectar Biosciences, Inc.
    Via GlobeNewswire
    News headline image
    Earnings Outlook For Cellectar Biosciences ↗
    Via Benzinga
    News headline image
    Cellectar Biosciences to Report Third Quarter Financial Results and Host a Conference Call on Thursday, November 13, 2025
    From Cellectar Biosciences, Inc.
    Via GlobeNewswire
    News headline image
    Cellectar Biosciences Receives Rare Pediatric Disease Designation from U.S. Food and Drug Administration for Iopofosine I 131 in Relapsed or Refractory Pediatric High-Grade Glioma
    From Cellectar Biosciences, Inc.
    Via GlobeNewswire
    News headline image
    Cellectar Biosciences Presented Promising Preclinical Data in Poster Presentation at the American Association for Cancer Research (AACR) Special Conference on Pancreatic Cancer Research
    From Cellectar Biosciences, Inc.
    Via GlobeNewswire
    News headline image
    12 Health Care Stocks Moving In Tuesday's Intraday Session ↗
    Via Benzinga
    News headline image
    Cellectar Biosciences Stock Drops 17% On $5.8M Fundraise: Retail Awaits An ‘Impending’ Rally ↗
    Via Stocktwits
    Topics Supply Chain
    News headline image
    Cellectar Biosciences, Inc. Enters Into Agreements to Raise $5.8 Million
    From Cellectar Biosciences, Inc.
    Via GlobeNewswire
    News headline image
    Cellectar Biosciences Announces European Medicines Agency (EMA) Confirms Eligibility to File for Conditional Marketing Authorization (CMA) for Iopofosine I 131 as a Treatment for Refractory (post-BTKi) Waldenstrom Macroglobulinemia (WM)
    From Cellectar Biosciences, Inc.
    Via GlobeNewswire
    News headline image
    Cellectar Biosciences Presented Compelling Data in Oral Session and Panel Discussions at the American Association for Cancer Research Special Conference on Discovery and Innovation in Pediatric Cancer
    From Cellectar Biosciences, Inc.
    Via GlobeNewswire
    News headline image
    Cellectar and Evestia Clinical Announce Partnership to Support Auger-Emitting Radiopharmaceutical Clinical Trial in Triple-Negative Breast Cancer (TNBC)
    From Cellectar Biosciences, Inc.
    Via GlobeNewswire
    News headline image
    Cellectar Biosciences and ITM Enter Supply Agreement for GMP-Grade Actinium-225
    From Cellectar Biosciences, Inc.
    Via GlobeNewswire
    News headline image
    Cellectar Biosciences to Participate at Oppenheimer 3rd Annual Targeted Radiopharmaceutical Therapies in Oncology Summit
    From Cellectar Biosciences, Inc.
    Via GlobeNewswire
    News headline image
    Cellectar Biosciences to Participate in Multiple Upcoming Medical Meetings and Industry Conferences in September
    From Cellectar Biosciences, Inc.
    Via GlobeNewswire
    News headline image
    Cellectar Biosciences to Present Data in Poster Presentation at the American Association for Cancer Research Special Conference on Advances in Pancreatic Cancer Research
    From Cellectar Biosciences, Inc.
    Via GlobeNewswire
    News headline image
    Cellectar Biosciences to Present Data in Oral Session and Panel Discussions at the American Association for Cancer Research Special Conference on Discovery and Innovation in Pediatric Cancer
    From Cellectar Biosciences, Inc.
    Via GlobeNewswire
    News headline image
    Cellectar Cuts Q2 Losses and Expenses ↗
    Via The Motley Fool
    News headline image
    Cellectar Biosciences Reports Second Quarter 2025 Financial Results and Provides a Corporate Update
    From Cellectar Biosciences, Inc.
    Via GlobeNewswire

    Frequently Asked Questions

    Is Cellectar Biosciences, Inc. - Common Stock publicly traded?
    Yes, Cellectar Biosciences, Inc. - Common Stock is publicly traded.
    What exchange does Cellectar Biosciences, Inc. - Common Stock trade on?
    Cellectar Biosciences, Inc. - Common Stock trades on the Nasdaq Stock Market
    What is the ticker symbol for Cellectar Biosciences, Inc. - Common Stock?
    The ticker symbol for Cellectar Biosciences, Inc. - Common Stock is CLRB on the Nasdaq Stock Market
    What is the current price of Cellectar Biosciences, Inc. - Common Stock?
    The current price of Cellectar Biosciences, Inc. - Common Stock is 2.800
    When was Cellectar Biosciences, Inc. - Common Stock last traded?
    The last trade of Cellectar Biosciences, Inc. - Common Stock was at 03/05/26 11:11 AM ET
    What is the market capitalization of Cellectar Biosciences, Inc. - Common Stock?
    The market capitalization of Cellectar Biosciences, Inc. - Common Stock is 8.94M
    How many shares of Cellectar Biosciences, Inc. - Common Stock are outstanding?
    Cellectar Biosciences, Inc. - Common Stock has 9M shares outstanding.
    Stock Quote API & Stock News API supplied by www.cloudquote.io
    Quotes delayed at least 20 minutes.
    By accessing this page, you agree to the Privacy Policy and Terms Of Service.
    © 2025 FinancialContent. All rights reserved.